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Abstract
Background: We initiated a prospective trial to identify transcriptional alterations associated with acquired chemotherapy
resistance from pre- and post-biopsy samples from the same patient and uncover potential molecular pathways involved in
treatment failure to help guide therapeutic alternatives.
Methodology/Principal Findings: A prospective, high-throughput transcriptional profiling study was performed using
endoscopic biopsy samples from 123 metastatic gastric cancer patients prior to cisplatin and fluorouracil (CF) combination
chemotherapy. 22 patients who initially responded to CF were re-biopsied after they developed resistance to CF. An
acquired chemotherapy resistance signature was identified by analyzing the gene expression profiles from the matched
pre- and post-CF treated samples. The acquired resistance signature was able to segregate a separate cohort of 101 newly-
diagnosed gastric cancer patients according to the time to progression after CF. Hierarchical clustering using a 633-gene
acquired resistance signature (feature selection at P,0.01) separated the 101 pretreatment patient samples into two groups
with significantly different times to progression (2.5 vs. 4.7 months). This 633-gene signature included the upregulation of
AKT1, EIF4B, and RPS6 (mTOR pathway), DNA repair and drug metabolism genes, and was enriched for genes overexpressed
in embryonic stem cell signatures. A 72-gene acquired resistance signature (a subset of the 633 gene signature also
identified in ES cell-related gene sets) was an independent predictor for time to progression (adjusted P=0.011) and survival
(adjusted P=0.034) of these 101 patients.
Conclusion/Significance: This signature may offer new insights into identifying new targets and therapies required to
overcome the acquired resistance of gastric cancer to CF.
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Introduction
Understanding how tumors evolve on a molecular level to
overcome the cytotoxic effects of chemotherapy is a critical step in
developing therapeutic approaches that will prevent or overcome
chemoresistance. However, due to the difficulties in obtaining
serial tumor biopsies from patients at various stages of therapy, the
identification of molecular alterations that occur as tumors become
resistant to therapy has been a vexing problem. The serial
collection of solid tumor samples from the same patients has been
extremely difficult in the clinical setting, but gastric cancer
provides a unique opportunity for this purpose, since it is often
initially responsive to chemotherapy and repeated endoscopies
may be performed to monitor tumor response to chemotherapy.
In this study, endoscopic biopsy samples were collected from
gastric cancer patients. We identified a gene expression signature
for acquired chemoresistance to cisplatin and fluorouracil (CF)
combination chemotherapy, by comparing samples collected prior
to CF therapy with samples taken from the same patients at the
time resistance to CF developed based upon objective clinical
progression. Using this approach, we could identify molecular
candidates that may possibly lead to development of new targeted
therapies for gastric cancer. Importantly, we also found that an
acquired chemoresistance signature could identify whether newly
diagnosed gastric cancer patients would have a short or more
sustained response CF therapy. Since the acquired resistance
signature is already highly represented in non-responders and that
it seems unlikely that the numerous expression changes occurring
on a global level would evolve in a relatively short period of time,
our results appear to support the conventional, clonal selection
model for tumor progression and acquired chemoresistance [1].
Identifying biomarkers that distinguish cancer patients who will or
will not benefit from cytotoxic chemotherapy will greatly improve
clinical management. Although studies using high-throughput
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attempted to identify such predictors, the performance of these
predictors has been mixed [2]. In part, this may be due to the
difficulty of identifying robust gene signatures in tumors from
populations with large genetic variation. Our data suggests that
expression-profiling of posttreatment samples could be a possible
alternative approach.
Some studies have suggested that tumors which develop
chemoresistance may acquire certain properties inherent to stem
cells, and that chemotherapy treatment leads to a concomitant
enrichment of cancer stem cells in vitro [3]. We further demonstrate
that the acquired resistance signature is enriched for genes
previously identified in embryonic stem (ES) cell expression
signatures, further suggesting that for gastric cancer, chemoresis-
tance arises from selection of pre-existing cells with particular stem
cell characteristics.
Materials and Methods
Patient accrual and follow-up
This is the part of a prospective trial approved by the
Institutional Review Board (IRB) of the National Cancer Center
Hospital in Goyang, Korea (NCCNHS01-003). All participants
signed an IRB-approved informed consent form. Eligibility for
enrollment into the study included the following parameters: 1)
age $18 years; 2) histologically-confirmed gastric adenocarcino-
ma; 3) clinically-documented distant metastasis; 4) no previous or
concomitant malignancies other than the gastric cancer; 5) no
prior history of chemotherapy, either adjuvant or palliative; and 6)
adequate function of all major organs. Patients who were lost to
follow-up before completing 6 cycles of chemotherapy, except for
documented progressive disease, were excluded from the analyses.
Our prospective trial had 2 objectives. The first objective, which
is the focus of another paper [4], was to develop a genomic
predictor for initial chemotherapy response by correlating the
expression profiling data of pretreatment samples with clinical
outcome (intrinsic resistance study). Sample size of the trial was
planned based on this first objective. For the training set, 91 events
were estimated to be required at a=0.001, b=0.05, t (standard
deviation of log intensity) = 0.75, and d (hazard ratio associated
with one-unit change of log intensity) = 2. Hence, 96
pretreatment samples were collected from August 2001 to January
2005 as the training set (for the intrinsic resistance study). A second
group of 27 eligible patients was enrolled as the array validation
cohort between February 2005 and April 2006, which includes 22
patients treated with CF, and 5 patients treated with cisplatin plus
oral capecitabine (a fluorouracil pro-drug considered equivalent to
fluorouracil; CX). CX therapy was demonstrated to be therapeu-
tically equivalent to the CF regimen for metastatic gastric cancer
[5].
The second objective of our prospective trial, which is pursued
by analyses presented in this paper, was to identify a gene
expression signature for the acquired chemoresistance by com-
paring pre- and post-treatment samples of the clinical responders
(acquired resistance study). After an initial endoscopic biopsy, all study
patients were prospectively treated and followed-up. Patients were
treated with cisplatin (60 mg/m
2, D1) in combination with either
fluorouracil (1 g/m
2 for 5 days; n=118) or capecitabine (Xeloda;
Roche; 1,250 mg/m
2 BID for 2 weeks; n=5)
5 every 3 weeks.
Chemotherapy doses were reduced depending upon toxicities and
the patient’s performance status. Specific dose modification
schemes for the subsequent treatment cycle were at the discretion
of the attending oncologist. The treatment schedule for fluoro-
uracil could be shortened at the discretion of the oncologist from 5
to 3 days for elderly patients ($70 years) or patients with a poor
performance status (Eastern Cooperative Oncology Group
(ECOG) performance status $2). Abdominal spiral computed
tomography (CT) scans were performed for all patients every 3
cycles of chemotherapy (i.e., 9 weeks). Objective response was
documented for patients with measurable disease according to
World Health Organization (WHO) criteria [6]. A partial response
(PR) was defined as more than a 50% decrease in the sum of the
products of the 2 largest perpendicular diameters of measurable
lesions for at least 4 weeks, but a confirmation CT was not
routinely performed 4 weeks after the initial documentation of PR.
There were 38 patients with PR among 96 training set (of the
intrinsic resistance study). Patients with PR underwent a follow-up
biopsy at the time disease progression was observed (i.e.,
progressive disease according to the WHO criteria), referred to
as the ‘‘chemoresistant state’’. Adequate biopsy samples from
tumors in a chemoresistant state were available from 22 patients
with PR (57.9%). Chemoresistance state biopsy samples of the
other 16 patients (42.1%) could not be profiled due to either
inadequate RNA quantity/quality or patients’ refusal. There was
no difference in age, sex, histological type, time to progression
(TTP), and overall survival between 22 re-biopsied patients and
the other 16 patients who had PR but were not re-biopsied.
Samples were collected at least 2 weeks after the last dose of the
fluorouracil and before second-line chemotherapy was started, in
order to minimize any acute drug effects on expression profile.
Two pieces of grossly-normal gastric mucosa tissue samples
were also collected from antrum of 21 healthy volunteers (Table
S1).
Identification of an acquired resistance signature to CF
Endoscopic biopsies were performed to obtain the fresh tissue.
Five to ten pieces of fresh tumor tissues were obtained from non-
necrotic portion of tumor using large cup biopsy forceps of
7.3 mm diameter (Olympus FB-24K-1, Olympus, Tokyo, Japan).
Then obtained fresh tissues were frozen in liquid nitrogen within
15 min of the first biopsy harvest. Tissue samples containing at
least 50% tumor cells were processed for RNA as previously
described [7]. One microgram of total RNA was amplified and
hybridized to an HG-U133A cartridge array, according to the
manufacturer’s protocol (Affymetrix, Santa Clara, CA). All
expression microarray data is available at the Gene Expression
Omnibus (GEO) Database (accession number GSE14210, http://
www.ncbi.nlm.nih.gov/geo) [CURRENTLY, REVIEWER AC-
CESS ONLY: http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token=rtgnlocqoqeiwtw&acc=GSE14210]. Gene expression
microarray data were normalized by Robust Multichip Average
(RMA) using R2.6. Pre- and post-CF expression data from 22
rebiopsied responders were normalized independently from the
expression data from a separate group of 101 non-rebiopsied
patients. Microarray data were analyzed using BRB ArrayTools
(version 3.6, National Cancer Institute, http://linus.nci.nih.gov/
BRB-ArrayTools.html) [8].
Gene expression changes that distinguished the initial tran-
scriptional status of tumors from gene expression patterns when
tumors became chemoresistant were determined for the 22
patients with documented initial response (PR) to CF therapy.
Matched microarray data was compared between the samples
obtained prior to CF treatment and samples collected after
resistance to therapy developed. These data were analyzed using
the class comparison algorithm of BRB-ArrayTools (random
variance model), which computes a paired t-test for each gene
using the RMA-summarized log-intensities for Affymetrix U133A
arrays. Genes differentially expressed between these 22 paired
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selection P-value cutoffs of 0.05 and 0.01, a permutation P value
was calculated, which is the proportion of random permutations
that identify a similar number of significant genes that are found
when comparing the true class labels.
Time to progression was plotted using the Kaplan-Meier
method. A log-rank test was used to determine differences between
survival curves. Wald’s test was used to assess the statistical
significance of the Cox hazard ratio. Multivariable regression
analyses were performed using a Cox proportional hazard model.
All these analyses were performed using SPSS (version 15.0; SPSS,
Inc., Chicago, IL). Multivariable ordinal logistic regression
analysis was performed using to SAS (version 9.1.3, SAS, Cary,
NC), to evaluate the association between the 72-gene predictive
index and radiographic response.
Transcription factor analysis
Transcription factor analyses were performed to look for the
enrichment of transcription factor targets in the genes comprising
the acquired resistance signature (BRB-ArrayTools). All genes
queried in this analysis algorithm have been catalogued to
transcription factor responsive categories based upon experimen-
tally-verified transcription factor responsiveness. Transcription
factor-binding curation information in the Transcriptional Regu-
latory Element Database (TRED) [9] was used to eliminate targets
without any experimental verification.
Analysis of public DNA microarray data from surgically
treated gastric cancer patients
Publicly accessible microarray data for surgically-treated gastric
patients generated by the Stanford Functional Genomics Facility
were also obtained from the NCBI GEO database (GSE4007) and
included about 30,300 genes common to these datasets. The
microarray data were generated and normalized as described in
Leung et al [10]. Batch effects in gene expression were removed
with probe-wise mean centering and missing data were imputed
with the nearest neighbor averaging method [11]. The array
cDNA clones were annotated using SOURCE (Stanford Micro-
array Database) and the Entrez GeneID was used as the mapping
identifier for the Affymetrix HG-U133A array.
Gene set comparison analyses
The gene set comparison tool analyzes user-defined gene sets for
differential expression among pre-defined classes of a source
dataset. For each source dataset, a P-value is computed for each
gene to correlate the expression level vs. survival time using a
proportional hazards model (or for the differential expression
between pre-defined classes, depending on the nature of the
phenotype), generating a ranked gene list of a given BRB-
ArrayTools project. For a set of N genes, the LS statistic is defined
as the mean negative natural logarithm of the P-values of the
appropriate single gene univariate tests [12]. A summary statistic is
computed that summarizes these P values over the user-defined
gene set; the summary statistic is average log(P) for the LS
summary of how the P values differ from a uniform distribution for
LS [12]. The summary statistic is related to the distribution of the
summary statistics for random samples of N genes, sampled from
those represented on the array. Here N is the number of genes in
the user-defined gene set. 100,000 random gene sets were sampled
to compute this distribution. The LS P value is the proportion of
random sets of N genes with smaller average summary statistics
than the LS summaries computed for the real data. This approach
is used for a variety of types of correlations between gene
expression levels and phenotype. The nature of the phenotype (for
instance, survival time or binary indicators) determines the
manner in which the gene specific P values are computed. An
LS P value less than 0.005 is considered significant.
Identification of a gastric cancer-specific signature and a
gastric cancer differentiation signature
Total RNA was isolated from frozen endoscopic biopsy samples
of the antral mucosa collected from 21 healthy volunteers and
analyzed by microarray as previously described. In order to
identify the gastric cancer-specific signature, we compared the
expression data from the 21 normal samples with 101 samples
from patients prior to chemotherapy samples (excluding 22
rebiopsied patients used to develop the acquired resistance
signature) using class comparison algorithms of BRB-ArrayTools.
Of the 101 patients, 41 patients had Lauren’s intestinal histological
type of primary tumors and 60 had the diffuse type. Mixed-type
tumors were categorized together with the diffuse type. A
differentiation signature was identified by comparing the gene
expression data from the 41 intestinal type samples with 60 diffuse
type samples using class comparison algorithms of BRB-ArrayTools.
Generation of ES cell signatures from published data
To generate a user-defined gene set for our gene comparison
analyses, we adopted several gene lists from the published work of
Ben-Porath et al [13], in which several gene sets associated with ES
cell identity were compiled for gene set comparison analyses. An
‘‘ES expression set’’ was previously defined by Ben-Porath et al [13]
as genes over-expressed in human ES cells in at least 5 out of 20
profiling studies [14]. This ES expression set was then amended
[13] so that genes in the ‘‘proliferation’’ Gene Ontology and the
proliferation cluster of breast cancer [13,15] were excluded and
referred to as the ES set without proliferation genes. Lists of target genes
for MYC [16], SOX2 [17], OCT4 [17], NANOG [17], SUZ12
[18], EED [18], and H3K27 [18], which are key transcription
factors in stem cells, were also adopted from Ben-Porath [13].
These genes were originally identified by chromatin immunopre-
cipitation array studies [16–18]. For our gene set comparison
analyses, Entrez IDs [13] of target genes were mapped to probe set
IDs on the HG-U133A array (www.NetAffx.com).
Identification of a 72-gene predictive index
Among the 468 genes upregulated at the chemoresistant state
(P,0.01), 72 unique genes were members of at least one of 4
published ES cell-related gene sets (‘‘ES set without proliferation genes’’
[13,15], the experimentally-validated MYC transcription factor
target gene set (TRED MYC_T00140) [9], and target genes of
MYC and SOX2 identified by a chromatin immunoprecipitation
array study [16,17]). A genomic predictor (referred to as the ‘‘72-
gene predictive index’’) was constructed by calculating the weighted
linear combination of log signal values of these 72 unique genes
overlapping between the acquired resistance signature and ‘‘ES cell-
related gene sets’’. The univariate t-statistics for comparing the classes
(acquired chemoresistant vs. pretreatment states) were used as the
weights.BRB-ArrayTools(theclassprediction)wasused tocalculate
the t-value of each gene. The predictive power of the 72-gene
predictive index was tested for time to progression and survival
using the Cox proportional hazards model.
Results
Identification of an acquired resistance signature to CF
Twenty-two patients who demonstrated a clinical response (PR)
to CF therapy were biopsied prior to the initiation of therapy and
Acquired Chemoresistance in Gastric Cancer
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Pre- and post-CF samples were not significantly different in the
tumor cell percentage and measures of microarray data quality
control (Table 1 and Table S2). Median interval between the 2
biopsies was 8.7 months (interquartile range, 6.4–12.6). Since the
permutation P values were consistently less than 0.05 at P cutoffs
for feature selection of 0.01 and 0.05 (permutation P values, 0.012
and 0.006, respectively), this demonstrates that gene expression is
significantly different between the chemoresistant and pretreat-
ment states. Genes differentially expressed between the pretreat-
ment state of 22 tumors that proved initially responsive to CF
chemotherapy and tumors from the same patients after having
evolved into an acquired chemoresistant state were identified as
the ‘‘acquired resistance signatures’’. 2,446 genes were identified
in the acquired resistance signature with a feature selection of
P,0.05, whereas 633 genes were identified using a feature
selection of P,0.01. The most highly represented functional
category in the acquired resistance signature was Protein Synthesis
(Table S3; Ingenuity Pathway Analysis [www.ingenuity.com]),
which includes AKT1, ribosomal subunit mRNAs (RPS6, RPL13,
RPL14, RPL15, RPL18, RPL29, RPL3, RPL30, RPL4, RPS11,
RPS19, RPS9), and eukaryotic translation initiation factors (EIF4B
EIF3D, EIF3E, EIF3F, EIF3H). Akt/mTOR and Ras–MAPK
signaling modules are two most-studied pathways that exhibit a
paramount effect on translational regulation [19]. Given the
concurrent upregulation of these key components of this pathway
(AKT1 (P=0.0012), EIF4B (P=0.0089), and RPS6 (P=0.0009)),
the PI3K/Akt/mTOR signal transduction pathway is presumed to
be activated in the acquired resistance state (Figure S1). AKT1 has
been linked to in vitro cisplatin resistance [20–22]. mTOR
inhibition has also been known to reverse in vitro acquired
resistance to endocrine therapy and EGFR inhibitors of breast and
lung cancers, respectively [23,24]. Since ERBB2 is also upregu-
lated in the acquired resistance signature (P=0.0065), ERBB2 may
play a role in the upregulation of Protein Synthesis-related genes,
through activation of the mTOR pathway [25].
Transcription factor gene set comparison analysis indicated that
the acquired resistance signature is enriched with targets of
multiple transcription factors, including a MYC target gene set
(TRED MYC_T00140) [9] (Table S4). This is consistent with a
microarray data in the literature that the majority of genes
responsive to Myc overexpression are involved in macromolecular
synthesis, protein turnover, and metabolism, including 30
ribosomal protein genes [26].
The acquired resistance signature segregates patients
according to the time to disease progression following
CF therapy, but is not prognostic in gastric cancer
patients treated only by surgery
We wished to determine whether expression of the acquired
resistance signature in gastric cancer tumors at initial diagnosis
was predictive of response to CF therapy. Expression of the
acquired resistance signature in a separate group of 101 non-
rebiopsied gastric cancer patients was determined and related to
the clinical outcome of the patients according to which major
hierarchical cluster the patients were grouped. In patients without
lesions initially measurable by diagnostic imaging, time to
progression (TTP) was measured from the initiation of CF therapy
to the time when a change in therapy was required due to
unequivocal disease progression. Hierarchical clustering of the 101
pretreatment samples was performed using the 2,446-gene
acquired resistance signature. Outcome as measured by TTP
was significantly different between patients in each of the two
Table 1. Clinicopathological Characteristics of Patient
Subgroups Used for This Analysis.
Rebiopsied
Non-
rebiopsied
(N=22) (N=101)
Baseline clinicopathological characteristic
Age (years)
Median 58 58
Interquartile range (52–63) (52–64)
Sex – no. (%)
Male 20 (90.9%) 76 (72.2%)
Female 2 (9.1%) 25 (27.8%)
Performance status (PS) – no. (%)
ECOG
1 PS 0 or 1 22 (100%) 94 (93.1%)
ECOG PS 2 or 3 0 (0.0%) 7 (6.9%)
Histological type – no. (%)
Lauren’s intestinal 8 (36.4%) 41(40.6%)
Lauren’s diffuse 14 (63.6%) 60 (59.4%)
Location of primary lesion – no. (%)
Upper 1/3 1 (0.5%) 15 (14.9%)
Middle 1/3 7 (31.8%) 31 (30.7%)
Lower 1/3 13 (59.1%) 51 (50.5%)
Entire stomach 1 (0.5%) 4 (4.1%)
Distant metastasis – no. (%) 22 (100%) 101 (100%)
Tumor cell percentage in sample – (%)
Median 60 60
Interquartile range (50–78) (50–70)
Treatment and outcome
Chemotherapy regimen – no. (%)
Cisplatin/Fluorouracil 22 (100%) 96 (95.0%)
Cisplatin/Capecitabine 0 (0%) 5 (5.0%)
Relative dose intensity - %
Median 73 80
Interquartile range 68–82 74–90
Number of chemotherapy cycles
Median 10 4
Interquartile range (9–15) (3–8)
Radiographic response (WHO
criteria) – no. (%)
PR
2 22 (100.0%) 28 (31.8%)
SD
3 0 28 (31.8%)
PD
4 0 32 (36.4%)
Nonmeasurable disease 0 13
Second-line chemotherapy – no. (%) 19 (86.4%) 69 (68.3%)
Median follow-up for survivors – mo. 35.5
Time to progression – mo.
Median 8 3.9
Interquartile range (5.6–12.5) (2.3–8.6)
Overall survival – mo.
Median 11.9 7.9
Interquartile range (11.3–21.1) (5.6–16.8)
1Eastern Cooperative Oncology Group,
2Partial Response,
3Stable Disease, and,
4Progressive Disease.
doi:10.1371/journal.pone.0016694.t001
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of the genes upregulated in the chemoresistant state had a
significantly shorter TTP than patients with lower expression of
these genes (Log-rank P value=0.033) (Figure 1A). In order to
further evaluate the association of these 2,446 genes with TTP of
101 patients, we also performed a survival risk prediction analysis
of BRB-ArrayTools, in which the entire 10-fold cross-validation
process was repeated using 2,446 genes and a log-rank statistic for
TTP between 2 predicted risk groups was obtained for each
random dataset with TTP data shuffled among 101 patients
[8,27]. The permutation P value for testing the null hypothesis that
there is no relation between 2,446 genes and TTP, which is the tail
area of this null distribution beyond the log-rank value obtained
for the real data, was estimated 0.06, suggesting a borderline
significance of the association. Patients in the cluster with
increased expression of 468 genes upregulated in the chemoresis-
tant state at P,0.01 also had a significantly shorter TTP than
patients with lower expression of these genes (Log-rank P
value=0.012) (Figure 1B). These results suggest that the acquired
resistance signature reflects real molecular profile of chemoresis-
tant clones, not nonspecific drug effects.
We also wished to further address whether these acquired
resistance signatures were predictive of CF response or represented
a general prognostic signature that could predict survival of 88
gastric cancer patients who were treated by surgery alone and not
by chemotherapy
10. Neither of the two acquired resistance
signatures (2,446 or 633 genes) was predictive of survival in the
surgically treated gastric cancer patients using the same hierar-
chical clustering method as above (Log-rank P values, 0.84 and
0.41, respectively). Thus, the acquired resistance signature is
predictive of patient response to CF and not just prognostic for
gastric cancer patients in general.
Figure 1. Hieraching clustering analyses of pretreatment samples using acquired resistance signatures. Hierarchical clustering
dendrograms of pretreatment samples from a separate set of 101 gastric cancer patients, using genes differentially expressed between the
pretreatment- and chemoresistant-states of 22 rebiopsied responders at various P cutoffs for feature selection. Kaplan-Meier plots for the time to
progression (TTP) calculated for each of the two major clusters generated by each dendrogram are shown below. (A) Hierarchical clustering of 101
pretreatment samples using the 2,446–gene acquired resistance signature (P for feature selection,0.05). Heatmap generated using a log2-
pseudocolor image with gene centering. Kaplan-Meier plots for TTP calculated for each of the two major clusters generated are shown below.
Patients in high risk cluster (n=60, high expression of the genes upregulated at chemoresistant state (upper) had a significantly shorter TTP than
patients in low risk cluster (n=41, low expression) (3.0 vs. 5.0 months; P=0.033). (B) Hierarchical clustering of the same 101 gastric cancer samples
using the 633–gene acquired resistance signature (P for feature selection,0.01). Patients in high risk cluster (n=38, high expression of genes
upregulated at chemoresistant state (upper) had a significantly shorter TTP than patients in low risk cluster (n=63, low expression) (2.5 vs. 4.7 months;
P=0.012).
doi:10.1371/journal.pone.0016694.g001
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Non-rebiopsied Patients at P,0.05.
Upregulated at Downregulated at
chemoresistant state
1 chemoresistant state
1
Gene HR
2 Gene HR Gene HR Gene HR Gene HR Gene HR Gene HR
DEXI 3.1 RPS20 4.4 INTS8 1.7 PA2G4 1.7 MINA 1.5 SLC29A2 1.5 CYorf14 0.6
TRAP1 1.9 TIMM10 1.9 COPS5 1.7 PSMD4 1.8 EIF4B 2.1 RPL3 2.4 SYTL2 0.7
HIST3H2A 1.7 LGTN 2.0 RPS19 2.4 C10orf2 1.5 PSMD4 1.6 FAU 1.9 PTPRD 2.3
RPL13P12 3.4 RPS19 2.5 SQLE 1.3 E2F5 1.4 ATP5G1 1.6 EXOSC4 1.4 SEC24D 0.6
RPL13 5.4 RPL13 3.0 POLR2G 1.8 SCRN3 0.5 APRT 1.5 DNAJB12 1.7 TLE4 0.4
RPS20 3.8 MPHOSPH10 2.2 MEST 1.3 EEF1B2 1.8 EXOSC5 1.4 RPS9 1.9 214101_s_at 1.6
ATIC 1.9 AOF2 1.8 SNRPD2 1.6 NAT10 1.6 OSBPL1A 0.8 CCNB1IP1 1.3 CASP1 0.7
EIF3H 2.7 NHP2L1 1.9 RPS18 3.1 CDK4 1.5 NOL7 1.5 EIF3L 1.8 KLHL2 0.5
NENF 2.6 CENPN 1.4 RRP12 1.7 CDK5RAP1 1.6 KLHDC3 1.6 MRPL11 1.4 SAT1 0.6
RPL8 2.3 PHB2 1.9 PKN2 0.8 SMYD5 1.7 SPTLC2 1.6 METRN 1.5 207799_x_at 2.4
RBMX 2.5 RNASEH2A 1.5 PHB 1.5 RANBP1 1.4 RPS5 1.8 DDB1 1.8 IL15 0.7
PRMT5 1.8 ADSL 1.6 PTK2B 0.6 H2AFY 0.7 TNFRSF11A 0.7 LONP1 1.6 ARNTL 0.5
PCBD1 1.8 COX4NB 1.8 MRPL13 1.6 RPS3 2.2 EIF2B4 1.6 RPL12 2.1 JAK2 0.7
FDPS 2.2 FXC1 2.3 DGUOK 2.2 VKORC1 1.6 POLG2 1.6 RPL3 2.7 GATA3 1.3
DAP3 2.3 ENY2 1.8 STOML2 1.5 DDX19A 1.8 EIF3C 1.6 GLG1 1.6 ANTXR1 2.3
LAS1L 1.9 NBAS 2.5 EEF1G 2.6 PFDN2 1.5 TRMT12 1.4 DDAH2 1.3 SEC24D 0.5
C15orf44 2.9 TBRG4 1.7 ELP3 1.9 IMP4 1.5 NRTN 2.2 CPNE3 1.5 EIF1AY 0.7
RAN 1.8 EIF4EBP1 1.4 RPL32 3.0 GCSH 1.5 TFDP2 1.4 ICT1 1.4 STX12 0.6
TRMT1 1.7 TBCB 1.6 HMBS 1.8 NELF 1.5 C14orf1 1.5 VARS 1.3 KCNJ15 0.8
UTP14A 1.6 POLR2C 2.1 MOSC1 1.6 LMNB2 1.6 RPL38 2.3 ITPA 1.8 LIMS1 1.5
SNRPE 1.9 Magmas 1.8 HTRA2 1.9 DDX28 1.5 RPL14 1.7 GP2 0.9 CCRL2 0.7
RPL13 3.8 RPP40 1.5 M10098_5_at 0.9 SSSCA1 1.5 ZNF259 1.6 SF3B2 1.9 CYP19A1 1.5
SNRPB 1.7 PCCB 1.7 NDUFA13 1.7 GNB2L1 1.8 NLE1 1.4 SGSM3 0.7 GATA3 1.3
PUS1 2.0 GTPBP4 1.6 DDX28 2.0 FOXJ1 1.6 CSE1L 1.3 RPL12 2.2 SPG20 0.7
RUVBL1 1.5 TH1L 1.5 NME1 1.4 M6PR 1.6 RPL15 2.0 FUS 1.5 JTV1 1.6
PUF60 1.9 UMPS 1.8 INTS5 1.9 MCM3 1.4 BANF1 1.4 YY1 1.5 AMPD1 0.7
RPL13 4.1 RPS15 2.2 CSE1L 1.4 MYLIP 1.5 C17orf90 1.7 EIF3CL 1.6 KCNJ15 0.7
NUP93 1.8 TRMT1 1.7 ADSL 1.6 CNPY2 1.6 MED18 0.5 CHCHD8 1.6 AZIN1 1.7
PPIE 2.1 IPO5 1.5 CSTF2 1.9 EEF1G 2.3 FLAD1 1.5 PSMB7 1.4 KLF10 1.5
RPL36A 2.4 CKAP5 1.8 PTRH2 1.6 DHX30 1.6 MAN1B1 2.0 RPL4 1.6 DDN 1.8
EIF3F 2.4 EIF3E 1.9 RPL24 2.2 PSMB4 1.7 FTSJ2 1.6 CDCA4 1.4 DDX3Y 0.7
CCT7 2.0 PES1 1.9 DDX31 1.7 ALDH7A1 1.5 DNPEP 1.6 PAAF1 1.3 SEMA3F 0.7
HSPC152 2.1 SNRPC 2.2 MMS19 1.7 TNFSF13 0.8 GPR172A 1.4 POLR2H 1.6 NR3C1 0.7
ERI3 1.9 MRPL15 1.6 WDR74 1.6 C16orf58 2.0 LOC552889 0.7 KATNB1 1.5 KLF2 0.8
TTC27 1.6 NHP2 1.7 SQLE 1.4 DDX49 1.8 CLNS1A 1.4 CHST5 1.5 LOC100130354 2.9
PMPCA 2.1 SMARCC1 1.5 POLR2I 1.5 MTX1 1.5 MCM7 1.3 C6orf48 1.3 ALK 2.7
EIF3D 2.2 RPP21 1.9 RDBP 1.5 ZNF593 1.4 MDN1 1.5 FLAD1 1.5 HS3ST3A1 1.4
RUVBL2 1.7 RPL6 2.6 NOP56 1.4 ATP1A1 0.7 CDC34 1.5 LY6E 1.2 SEC24A 0.7
TDP1 1.8 APEX1 1.6 TJP3 0.8 NFATC2IP 0.7 TEX264 1.7 NUDC 1.4 PTPRR 0.8
MRPL24 1.9 TMEM147 1.6 RPS21 1.8 MRPS28 1.4 APRT 1.5 TRAPPC2L 1.5 EDA 1.6
KARS 2.2 NSUN5 1.7 EHF 0.8 CPSF1 1.5 OPA3 0.6 AGFG1 0.7 EIF2C4 0.5
PPIE 1.9 CNPY3 1.6 NOL7 1.6 MACROD1 1.4 MRPS7 1.5 RPLP0P6 1.7 INHBC 1.4
LIG3 2.1 CIAPIN1 2.0 TUFM 1.7 GADD45GIP11.4 TUSC4 1.8 RPL29 1.6 SEZ6L 1.7
RPL31 3.3 HMGA1 1.4 LANCL2 1.5 GP2 0.8 GPR175 1.7 EIF1AY 0.9
RPL10A 2.3 BCAT2 1.6 ANAPC5 1.6 POLR1C 1.5 GPSN2 1.4 SLC6A6 0.5
RPL30 3.2 RPL18 2.2 SMARCA4 1.6 RPL12 2.4 TTC38 0.7
RPL4 2.2 POP5 1.8 RNF8 1.8 PRPF3 1.6 FAM86B1 1.4
C8orf55 1.6 CSNK1A1 0.6 EMG1 1.5 EEF1G 2.4 LSM4 1.4
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Upregulated at Downregulated at
chemoresistant state
1 chemoresistant state
1
Gene HR
2 Gene HR Gene HR Gene HR Gene HR Gene HR Gene HR
RPL4 2.2 MED20 1.6 PACSIN3 1.7 KAT2A 1.6 THG1L 1.6
DDX1 1.7 CCT3 1.6 THAP11 1.9 TSFM 1.7 MRPS2 1.4
1Sorted according to the increasing order of P value for TTP correlation.
2The ratio of hazards of disease progression of 101 patients for a two-fold change in the gene expression level.
doi:10.1371/journal.pone.0016694.t002
Figure 2. Acquired resistance signature and stem cell signature. (A) Hierarchical clustering of 101 pretreatment patient samples using the ‘‘ES
set without proliferation genes signature’’. Kaplan-Meier plots for time to progression (TTP) of patients in each cluster generated are shown on the
right side. Patients in high risk cluster (I) (n=44, high expression of ‘‘ES set without proliferation genes’’) had a significantly shorter TTP than patients
in the low risk cluster (II) (n=57, low expression) (2.7 vs. 4.7 months; Log-rank P value=0.014). (B) Principal component analysis plot using a published
U133A microarray meta-analysis dataset [14] containing 24 human ES cell samples (shown in red) and 193 various fetal and adult differentiated tissue
samples (shown in green) using the 633-gene acquired resistance signature (feature selection P,0.01). Each sphere represents a single sample.
Samples whose expression profiles of 633 genes are similar are shown close together. (C) a. Expression of the 633-gene acquired resistance signature
using the same published meta-analysis microarray data
14 as in (B). Heatmap generated using a log2-pseudocolor image with gene centering. Red
and green colors represent high and low gene expression levels, respectively. Genes upregulated at the chemoresistant state of our study patients
(post/pre.1, I) show coordinated overexpression in ES cells (left), while genes downregulated at the chemoresistant state (post/pre,1, II) show
coordinated overexpression in differentiated tissue samples (right). b. Expression of the same 633-gene acquired resistance signature in 101
pretreatment samples collected from a separate set of gastric cancer patients. Each row represents each patient, sorted according to the increasing
order of TTP from left to right, as matched with Kaplan-Meier curves for TTP of 101 patients (top right). Genes upregulated at the chemoresistant state
of our study patients (I) show the concordant overexpression in patients with shorter TTP (left), while genes downregulated at the chemoresistant
state (II) show the concordant overexpression in patients with longer TTP (right).
doi:10.1371/journal.pone.0016694.g002
Acquired Chemoresistance in Gastric Cancer
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e16694The acquired resistance signature shares many features
with the intrinsic resistance signature, but not with a
gastric cancer-specific signature or a gastric cancer
differentiation signature
These acquired resistance signatures were then compared with
the intrinsic drug resistance signature of a separate group of 101
non-rebiopsied patients, using gene setcomparison analysis of BRB-
ArrayTools [12]. Briefly, this algorithm computed a P-value for
eachof 2,446 genes to correlate the expression level vs. TTP of these
101 patients using a proportional hazards model. Then it computed
mean negative natural logarithm of the P-values of the single gene
univariate tests (LS statistic of this set of 2,446 genes) and the
proportion of random sets of 2,446 genes with smaller average
summary statistics than the LS summaries computed for the real
data (LS P value). The same analysis was repeated for 633 genes
selected at P,0.01. Consistent with results of the hierarchical
clustering analyses, the acquired resistance signatures were found to
be highly enriched in the ‘‘intrinsic resistance signature’’ of a
separate group of 101 CF-treated patients. LS re-sampling P values
were ,10
25 for both user-defined gene sets selected with different
cutoffs to define the acquired resistance signature (i.e., for 2,446 and
633 genes). Genes overlapping between acquired and intrinsic
resistance signatures are listed in Table 2. Figure 2Cb graphically
displays that 468 genes upregulated at the chemoresistant state of 22
rebiopsiedpatients (P,0.01) show the concordant overexpression in
non-rebiopsied patients with shorter TTP, while 165 genes
downregulated at the chemoresistant state show the concordant
overexpression in patients with longer TTP.
Using similar gene set comparison analyses, acquired resistance
signatures were then compared with ‘‘gastriccancer-specific signature’’ and
‘‘gastric cancer differentiation signature’’ of these 101 patients. To compare
the acquired resistance signature with ‘‘gastric cancer-specific signature’’,
the LS statistic of 2,446 genes in the acquired resistance signature was
estimated by computing a mean negative natural logarithm of the P-
values of the single gene univariate tests for differential expression of
each of 2,446 genes between 101 gastric cancer patients and 21
healthy volunteers. No significant overlap in gene expression was
observed comparing the acquired resistance signature to a ‘‘gastric
cancer-specific signature’’ (LS P value=0.96; Table S5). Similarly, there
was no significant overlap between the 2,446-gene acquired
resistance signature and a‘‘gastric cancer differentiation signature’’ that we
identified through the comparison of gene expression between
Lauren’s intestinal- (n=41) vs. diffuse-type (n=60) tumors, either (LS
P value=0.024; Table S5). These results further suggest that the
acquired resistance signature represents a set of genes dysregulated in
association with chemoresistance, and not cancer in general.
The acquired resistance signature shares features with
stem cell signatures
Given that complex regulatory networks in stem cells can be
best detected by expression analysis of many genes, we performed
several gene set comparison analyses comparing our acquired
resistance signatures with published ES cell signatures as reported
by Ben-Porath et al
13 (Table S6). We hypothesized that comparing
the acquired resistance signature with ES cell signatures would be
informative, since it has been suggested that cancer progenitor
cells possess stem cell-like traits [28].
Our acquired resistance signature, unlike the gastric cancer-specific
signature or the gastric cancer differentiation signature, was found to be
highly enrichedforgenes contained in the ES expressionset(defined as
genes over-expressed in at least 5/20 human ES cells profiling
studies [14]) (LS P value=3.0610
23; Tables S5 and S6). Since ES
cells are highly proliferative in vitro while stem cells are generally
quiescent in vivo, the ‘‘ES expression set’’ was modified
13 to exclude
genes listed in the ‘‘proliferation’’ category of Gene Ontology and
the proliferation cluster of breast cancer
15. This amended ES
expression set (designated the ES set without proliferation genes) could
also segregate the 101 pretreatment tumor samples according to
time to progression. Patients in the high risk cluster (n=44, high
expression of ‘‘ES set without proliferation genes’’) had a significantly
shorter TTP than patients in the low risk cluster (n=57, low
expression) (2.7 vs. 4.7 months; Log-rank P value=0.014)
(Figure 2A). Notably, the overlap between ‘‘ES set without proliferation
genes’’ and our acquired resistance signature was still statistically
Table 3. Seventy-two Unique Genes Which Belong to ES cell-
related Gene Sets (‘‘ES Set without Proliferation Genes’’ and
MYC/SOX2-Target Genes) and Were Upregulated in the
Chemoresistant State at P,0.01.
Probeset Gene t-value
1 Probeset Gene t-value
202840_at TAF15 5.2 200901_s_at M6PR 3.0
210350_x_at ING1 4.2 210416_s_at CHEK2 3.0
201247_at SREBF2 3.9 37950_at PREP 3.0
203391_at FKBP2 3.9 209134_s_at RPS6 3.0
218481_at EXOSC5 3.8 208619_at DDB1 3.0
210014_x_at IDH3B 3.7 33132_at CPSF1 3.0
208714_at NDUFV1 3.7 217792_at SNX5 3.0
204133_at RRP9 3.6 202857_at TMEM4 3.0
203103_s_at PRPF19 3.6 211595_s_at MRPS11 3.0
212563_at BOP1 3.6 209147_s_at PPAP2A 2.9
217874_at SUCLG1 3.5 200812_at CCT7 2.9
208676_s_at PA2G4 3.5 201039_s_at RAD23A 2.9
202339_at SYMPK 3.4 209029_at COPS7A 2.9
221809_at RANBP10 3.4 201391_at TRAP1 2.9
201487_at CTSC 3.4 200658_s_at PHB 2.9
211975_at ZNF289 3.4 212357_at KIAA0280 2.9
202072_at HNRNPL 3.3 218405_at ABT1 2.9
202649_x_at RPS19 3.3 200637_s_at PTPRF 2.9
209509_s_at DPAGT1 3.3 218049_s_at MRPL13 2.9
208907_s_at MRPS18B 3.3 212191_x_at RPL13 2.9
221669_s_at ACAD8 3.3 200695_at PPP2R1A 2.8
217940_s_at FLJ10769 3.3 201834_at PRKAB1 2.8
200980_s_at PDHA1 3.3 218866_s_at POLR3K 2.8
209196_at WDR46 3.3 213175_s_at SNRPB 2.8
210859_x_at CLN3 3.2 210027_s_at APEX1 2.8
202926_at NAG 3.2 218670_at PUS1 2.8
200824_at GSTP1 3.2 209669_s_at SERBP1 2.8
219979_s_at C11orf73 3.2 212032_s_at PTOV1 2.8
208101_s_at URM1 3.1 200022_at RPL18 2.8
208950_s_at ALDH7A1 3.1 200819_s_at RPS15 2.8
200874_s_at NOL5A 3.1 204175_at ZNF593 2.8
203039_s_at NDUFS1 3.1 209224_s_at NDUFA2 2.8
201732_s_at CLCN3 3.1 209148_at RXRB 2.8
202699_s_at TMEM63A 3.1 216105_x_at PPP2R4 2.8
200834_s_at RPS21 3.1 217753_s_at RPS26 2.8
201871_s_at LOC51035 3.0 221475_s_at RPL15 2.8
doi:10.1371/journal.pone.0016694.t003
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PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e16694Figure 3. Hierarchical clustering analyses of pretreatment samples using the 72 genes. (A) Hierarchical clustering of the 101 gastric cancer
samples using the 72 genes that are upregulated at chemoresistant state (P,0.01) and belong to ‘‘ES cell-related gene sets’’. (B) Patients in high risk
cluster according to (A) (n=51, high expression of 72 genes) had a significantly shorter time to progression (TTP) than patients in low risk cluster
(n=50, low expression) (2.7 vs. 4.0 months; P=0.025). (C) Patients in high risk cluster according to (A) (n=51, high expression of 72 genes) had a
significantly shorter survival than patients in low risk cluster (n=50, low expression) (6.8 vs. 9.2 months; P=0.028).
doi:10.1371/journal.pone.0016694.g003
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23). Among individual stem cell
transcription factor target gene sets, target genes of MYC [16] and
SOX2 [17], which are known to be overexpressed in ES cells [13],
were enriched in the acquired resistance signature (LS P values,
1.0610
25 and 4.3610
24, respectively), while target genes of
NANOG or OCT4 were not (Table S6). Figure 2Ca depicts the
graphic representation of the coordinated over- or under-expression
of genes upregulated in the chemoresistant state in published
microarray data [14] for ES- and differentiated-cells, respectively.
We, therefore, wished to test a hypothesis that ES cell signatures
might actually represent a core set of genes associated with in the
acquired resistance. We focused on gene sets representing ES cell
signatures that significantly overlap with the acquired resistance
signature - i.e.,‘ ‘ ES set without proliferation genes’’ and target genes of
MYC and SOX2 - (designated ES cell-related gene sets). Since these
gene sets are known to be overexpressed in ES cells
13, we extracted
72 unique genes, which belong to these ‘‘ES cell-related gene sets’’ and
were upregulated in the chemoresistant state at P,0.01 (desig-
nated the 72-gene acquired resistance signature; Table 3), from 633
genes in the acquired resistance (P,0.01). Using this ‘‘72-gene
acquired resistance signature’’, hierarchical clustering was performed
using a separate set of 101 pretreatment gastric cancer samples
from patients who were subsequently treated with CF and were
not re-biopsied. This generated two main clusters (Figure 3A)
where patients in the high expression cluster exhibited more rapid
disease progression and poorer survival than patients in the cluster
with lower expression (Log-rank P values, 0.025 and 0.028)
(Figures 3B and 3C). The multivariable regression analyses
demonstrated that the 72-gene predictive index, as a continuous
variable, is an independent predictor for time to progression,
overall survival, and radiographic response, after adjusted for age,
sex, and performance status (Table 4). Prominent among these 72
genes are anti-apoptotic genes (TRAP1 [29], CLD3 [30]) and DNA
repair (RAD23A [31], DDB1 [32]) and detoxifying enzymes
(GSTP1 [33,34]), which are associated with chemotherapy
resistance in vitro. Notably, 50 out of these 72 genes are MYC
target genes [26]. MYC is sufficient to reactivate an ES cell-like
gene expression program in normal human cells and human
cancer cells [35]. MYC overexpression has been shown to lead to
cisplatin resistance in several in vitro models [36–39].
Discussion
A major finding of this study is the identification of a gene
signature that emerged in association with tumor resistance to CF
therapy in patients who initially benefited from CF therapy. Prior
genomic predictors for the chemotherapy response, which were
developed using pretreatment tissue samples, have demonstrated a
mixed performance [1,2]. Here we demonstrate that the posttreat-
ment samples collected at the time of acquired resistance, although
difficult to obtain clinically, contain unique genomic information
that can be used to predict the initial response to cytotoxic
chemotherapy. No prior studies have explored acquired resistance
using genome-wide analysis of clinical samples, although 2 prior
studies evaluated the gene expression pattern in residual disease
after the completion of neoadjuvant chemotherapy [40,41]. Lee,
et al. demonstrated that postchemotherapy tumor gene signatures
outperforms baseline signatures and clinical predictors in predicting
for pathological response and progression-free survival [42],
although these investigators collected posttreatment breast tumors
3 weeks after chemotherapy, not at the time of progressive disease as
in our study. Our data is consistent with the aforementioned study
[42] that comparing postchemotherapy and prechemotherapy gene
expression signatures might be a feasible approach to the
identification of predictive signatures. Also, our data provides the
first genomic evidence in clinical samples supporting a conventional
model for the emergence of acquired resistance whereby resistance
emerges through a selective, clonal outgrowth of small populations
of pre-existing, chemoresistant tumor cells [3].
While the ‘‘72-gene acquired resistance signature’’ was developed
mainly for potential clinical utility, it contains several overexpressed
genes that have been shown to lead to chemoresistance. TRAP1
overexpression leads to 5-fluorouracil-, oxaliplatin- and irinotecan-
resistant phenotypes in different neoplastic cells [29]. Silencing of
hHR23A, a nucleotide excision repair (NER) enzyme, decreases the
nuclear DRP1 level and cisplatinresistanceinlung adenocarcinoma
Table 4. Multivariable Regression Analyses of the 72-gene Predictive Index in 101 Separate (Non-rebiopsied) Gastric Cancer
Patients.
Time to progression
1 Overall survival
1 Radiographic response
2
P HR
3 (95% CI
4) P HR (95% CI) P OR
5 (95% CI)
72-gene predictive index
6 0.011 1.01 (1.001–1.009)
7 0.034 1.004 (1.000–1.008) 0.036 1.008 (1.001–1.016)
Poor performance status
(ECOG PS
8 2–3)
9 0.048 2.31 (1.009–5.266) 0.049 2.240 (1.005–4.992) 0.452 1.847 (0.373–9.139)
Age
10 0.268 0.99 (0.965–1.010) 0.953 0.999 (0.976–1.023) 0.215 0.974 (0.934–1.015)
Female 0.100 1.57 (0.917–2.675) 0.156 1.462 (0.865–2.469) 0.564 1.370 (0.470–3.995)
1Result of the Cox regression analysis performed for 101 patients.
2Result of the ordinal logistic regression analysis performed only in 88 patients with measurable disease, using 3 categories of the dependent variable (PR, SD, and PD).
3Hazard ratio.
4Confidence interval.
5Odds ratio.
6Weighted linear combination of log signal values of 72-gene acquired resistance signature. The univariate t-statistics for comparing the acquired chemoresistant state
with the pretreatment state were used as the weights.
7Hazard ratio for each unit increase in 72-gene predictive index, which ranges from 1,783 to 2, 075 (i.e., the highest predictive index (2,075) and median predictive index
(1,945) are associated with hazard ratios of 4.3 (=1.005
292) and 2.2 (=1.005
162), respectively, compared with a hazard ratio of 1.0 with the lowest predictive index
(1,783) of all 101 samples).
8Eastern Cooperative Oncology Group Performance Status.
9as compared with ECOG PS 0 or 1.
10Hazard ratio for each year increase in age.
doi:10.1371/journal.pone.0016694.t004
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cisplatin resistant cancer cell lines [32]. Elevated glutathione S-
transferase P1 expression has been associated with resistance to
cisplatin-based chemotherapy in several cancer cell lines [33,34].
Our gene set comparison analyses demonstrate a significant
overlap between the ES cell signatures and our chemotherapy
resistance signatures. No prior studies have demonstrated the
enrichment of ES cell signatures in clinical samples collected at the
time of acquired resistance to cytotoxic chemotherapy. Accumu-
lating evidence suggests an association between a stem cell
phenotype and intrinsic chemoresistance [43–45]. Animal studies
have suggested that the cell population exhibiting cancer stem cell
characteristics is enriched in xenograft tumors following chemo-
therapy [46,47]. While ES cell signatures may not perfectly reflect
the phenotype of gastric cancer stem cells (which have not been
defined yet), the enrichment of ES cell signatures in chemoresis-
tant tumors may reflect the survival advantage of tumor cells
expressing stem cell regulatory networks. This was validated by
our finding that 72 genes shared by the acquired resistance and ES
cell signatures were sufficient to predict the initial response to CF.
This study has identified a molecular signature for acquired
resistance to CF therapy in gastric cancer patients. This signature
is able to identify patients likely to have a short or longer term
response to CF suggesting it reflects the molecular profile of
chemoresistant clones and not non-specific drug effects. Genes
contained within this signature, such as Akt/mTOR pathway
genes, TRAP1, RAD23A, and GSTP1, may be potentially useful
targets for treating tumors resistant to CF therapy. Future studies
will be required to confirm these results and to determine whether
our novel approach to develop an acquired resistance signature
that predicts the therapeutic response of patients to specific
chemotherapies is applicable to other types of cancer.
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